Fate Therapeutics Inc (FATE.OQ)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|68||Independent Chairman of the Board|
|44||2015||President, Chief Executive Officer, Principal Executive Officer, Director|
|57||Vice Chairman of the Board|
|2017||Senior Vice President - Corporate Development|
|47||2015||Chief Scientific Officer|
- BRIEF-Fate Therapeutics Announces Additional Clinical Data From Phase 1 Stage Of Protect Clinical Trial Of Protmune
- BRIEF-Fate Therapeutics Q4 Loss Per Share $0.29
- BRIEF-Fate Therapeutics Announces First Subject Treated With Fate-NK100 In Dimension Study For Advanced Solid Tumors
- BRIEF-Fate Therapeutics Announces Pricing Of Public Offering Of Common Stock
- BRIEF-Fate Therapeutics announces initial clinical data from ongoing first-in-human voyage study of FATE-NK100